Policy Impact Analysis - 117/HR/9378

Bill Overview

Title: Sunshine Act of 2022

Description: This bill specifies that manufacturers of drugs, devices, biologics, or medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program (CHIP) are not required to report peer-reviewed journals, journal reprints, journal supplements, medical conference reports, or medical textbooks that are provided to health care practitioners or teaching hospitals.

Sponsors: Rep. Burgess, Michael C. [R-TX-26]

Target Audience

Population: Healthcare Practitioners Affected by the Reporting Changes

Estimated Size: 1200000

Reasoning

Simulated Interviews

Cardiologist (New York, NY)

Age: 45 | Gender: male

Wellbeing Before Policy: 8

Duration of Impact: 5.0 years

Commonness: 5/20

Statement of Opinion:

  • I'm glad the paperwork is reduced, giving me more time with patients.
  • The unreported materials help me stay updated on cutting-edge treatments.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 8 8
Year 2 8 8
Year 3 8 8
Year 5 9 8
Year 10 9 8
Year 20 8 8

Oncology Nurse (Miami, FL)

Age: 37 | Gender: female

Wellbeing Before Policy: 7

Duration of Impact: 3.0 years

Commonness: 8/20

Statement of Opinion:

  • I’m concerned about not having detailed reporting on journals, as it might limit transparency.
  • It's crucial for the ongoing education of healthcare staff.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 7 7
Year 2 7 7
Year 3 7 7
Year 5 7 7
Year 10 7 7
Year 20 7 7

Hospital Administrator (Chicago, IL)

Age: 50 | Gender: female

Wellbeing Before Policy: 6

Duration of Impact: 10.0 years

Commonness: 4/20

Statement of Opinion:

  • This policy simplifies administrative processes without impacting funding, which is a relief.
  • It could pressure manufacturers to provide more transparent data through other channels.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 7 6
Year 2 7 6
Year 3 7 6
Year 5 8 6
Year 10 8 6
Year 20 8 6

Pharmaceutical Sales Representative (Seattle, WA)

Age: 32 | Gender: male

Wellbeing Before Policy: 5

Duration of Impact: 5.0 years

Commonness: 2/20

Statement of Opinion:

  • This change might ease my reporting workload and let me focus on relationships with providers.
  • Offers less bureaucratic hassle, but also less transparency to leverage.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 6 5
Year 2 6 5
Year 3 6 5
Year 5 7 5
Year 10 7 5
Year 20 7 5

Medical Student (Austin, TX)

Age: 29 | Gender: female

Wellbeing Before Policy: 7

Duration of Impact: 2.0 years

Commonness: 6/20

Statement of Opinion:

  • The impact on my education seems minimal right now, but I worry about future access.
  • I value any material that aids learning, reported or not.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 7 7
Year 2 7 7
Year 3 7 7
Year 5 7 7
Year 10 7 7
Year 20 7 7

Family Physician (Cleveland, OH)

Age: 56 | Gender: male

Wellbeing Before Policy: 6

Duration of Impact: 7.0 years

Commonness: 10/20

Statement of Opinion:

  • Any reduction in reporting requirements is welcome to reduce my overhead.
  • I hope it doesn't limit the quality of free educational resources available.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 7 6
Year 2 7 6
Year 3 7 6
Year 5 7 6
Year 10 7 6
Year 20 7 6

Pharmaceutical Company Executive (Los Angeles, CA)

Age: 40 | Gender: male

Wellbeing Before Policy: 8

Duration of Impact: 10.0 years

Commonness: 3/20

Statement of Opinion:

  • Simplifying these requirements cuts legal costs and makes compliance easier.
  • I see this as beneficial for everyone involved in the drug delivery process.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 9 8
Year 2 9 8
Year 3 9 8
Year 5 9 8
Year 10 9 8
Year 20 8 8

Health Policy Analyst (Boston, MA)

Age: 62 | Gender: female

Wellbeing Before Policy: 7

Duration of Impact: 5.0 years

Commonness: 2/20

Statement of Opinion:

  • The lack of mandated transparency could hinder informed decision-making, but reduces unnecessary costs.
  • Educational resources should remain openly available.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 7 7
Year 2 7 7
Year 3 7 7
Year 5 7 7
Year 10 6 7
Year 20 6 7

Clinical Research Coordinator (San Francisco, CA)

Age: 48 | Gender: female

Wellbeing Before Policy: 5

Duration of Impact: 4.0 years

Commonness: 5/20

Statement of Opinion:

  • The change might influence the dissemination of knowledge negatively.
  • Less oversight might be a double-edged sword in clinical transparency.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 5 5
Year 2 5 5
Year 3 5 5
Year 5 5 5
Year 10 5 5
Year 20 5 5

Health IT Specialist (Denver, CO)

Age: 36 | Gender: other

Wellbeing Before Policy: 6

Duration of Impact: 3.0 years

Commonness: 7/20

Statement of Opinion:

  • Reduced reporting requirements might decrease the demand for compliance monitoring services.
  • I'm intrigued by how this will change my work scope.

Wellbeing Over Time (With vs Without Policy)

Year With Policy Without Policy
Year 1 6 6
Year 2 6 6
Year 3 6 6
Year 5 6 6
Year 10 6 6
Year 20 6 6

Cost Estimates

Year 1: $0 (Low: $0, High: $50000)

Year 2: $0 (Low: $0, High: $50000)

Year 3: $0 (Low: $0, High: $50000)

Year 5: $0 (Low: $0, High: $50000)

Year 10: $0 (Low: $0, High: $50000)

Year 100: $0 (Low: $0, High: $50000)

Key Considerations